Q4 2025 · 13F-HR
Ally Bridge Group (NY) LLCholdings as filed
Filed 2026-02-17 · accession 0001193125-26-055035
The Brief · Ally Bridge Group (NY) LLC · Q4 2025
AI · grounded in 13F
Ally Bridge Group (NY) LLC closed its position in Madrigal Pharmaceuticals Inc MDGL, reducing exposure by $14.98M. The fund also exited positions in Ascendis Pharma A/S - ADR and Lenz Therapeutics Inc LENZ, the latter resulting in a $8.17M decrease. To offset these exits, the fund established new positions in Edgewise Therapeutics Inc for $11.04M and Abivax SA for $9.44M. Additional new entries include Inventiva SA IVA with a $6.98M investment and Minerva Neurosciences Inc NERV at $6.66M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76029N106 | REPL | REPLIMUNE GROUP INC | $11.7M | 12.2% | 1,200,000 | CALL | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $9.4M | 9.83% | 70,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $7.8M | 8.10% | 168,029 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $7.6M | 7.91% | 1,100,000 | CALL | SOLE |
| N0731H103 | ATAI | ATAI BECKLEY NV | $7.0M | 7.30% | 1,713,105 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $7.0M | 7.27% | 1,500,000 | Common | SOLE |
| 603380205 | NERV | MINERVA NEUROSCIENCES INC | $6.7M | 6.93% | 1,655,500 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $6.2M | 6.46% | 250,000 | PUT | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $5.9M | 6.10% | 19,882 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $4.8M | 5.04% | 195,000 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $4.8M | 4.99% | 200,000 | CALL | SOLE |
| 29842P105 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $3.0M | 3.13% | 397,895 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $2.9M | 3.03% | 1,785,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $2.8M | 2.86% | 500,000 | CALL | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $2.5M | 2.62% | 457,132 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $2.3M | 2.43% | 413,625 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $2.0M | 2.06% | 817,939 | Common | SOLE |
| 74346M505 | PMN | PROMIS NEUROSCIENCES INC | $1.7M | 1.77% | 249,339 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.